Popular search terms:
Search Results Label
36 results found-
Seqirus Announces US FDA Approval of Pandemic Influenza Vaccine
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine -
Seqirus | Latest News
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.
https://www.seqirus.us/news/seqirus-applauds-the-executive-order-to-accelerate-enhanced-protection-against-influenza-threats -
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
https://www.seqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal and Pandemic Influenza Vaccines
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines -
Seqirus | Annual Disclosures
Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.
https://www.seqirus.us/our-company/corporate-responsibility/disclosures -
Seqirus announces major advances in pandemic preparedness
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.
https://www.seqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.us/news/seqirus-releases-first-shipment-for-2019-2020-season -
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
https://www.seqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older -
New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
https://www.seqirus.us/news/new-scientific-data-comparing-circulating-influenza-b-viruses